Abbott licenses Reata's CKD candidate outside the US for $450 million

Abbott Laboratories and Reata Pharmaceuticals have entered into a collaboration agreement to develop and commercialise bardoxolone methyl, which is currently in late Phase II trials for the treatment of chronic kidney disease (CKD).